Targeted gene therapy and cell reprogramming in Fanconi anemia

Area of Science:

• Genetics and genomics
• Cell biology
• Regenerative medicine

Background:

• Fanconi anemia (FA) is a DNA repair deficiency syndrome impacting homology-directed repair.
• The therapeutic potential of gene targeting for FA remains unexplored.

Purpose of the Study:

• To investigate the feasibility of gene targeting for correcting FA.
• To assess the efficiency of targeting the FANCA gene into the AAVS1 safe harbor locus in FA patient fibroblasts.
• To evaluate the potential for generating disease-free hematopoietic cells through reprogramming and differentiation.

Main Methods:

• Utilized zinc finger nucleases and integrase-defective lentiviral vectors for gene targeting.
• Targeted FANCA gene into the AAVS1 safe harbor locus in Fanconi anemia type A (FA-A) patient fibroblasts.
• Reprogrammed gene-edited fibroblasts into induced pluripotent stem cells (iPSCs) and differentiated them toward the hematopoietic lineage.

Main Results:

• Achieved efficient and specific gene targeting of FANCA into the AAVS1 locus in up to 40% of FA fibroblasts.
• Confirmed successful integration of FANCA in all tested FA-iPSC clones.
• Generated disease-free hematopoietic progenitors from gene-edited FA-iPSCs.

Conclusions:

• Demonstrated the feasibility of correcting FA using gene targeting and cell reprogramming.
• This strategy shows promise for treating DNA repair deficiency syndromes.
• Gene targeting offers a potential therapeutic avenue for Fanconi anemia.